Subtype
Malignant Bone Neoplasm
CI-CAN-00001109Explore in graph →
38 active trials4 approved drugs8 evidence items
- NCIt
- C4016
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001109Explore in graph →
Clinical trials
152 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | suspended | Phase 2 / Phase 3 | 1,122 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 | clinicaltrials |
| NCT07193550 | A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | recruiting | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial(PEARL RCT) | not yet recruiting | Phase 2 | 46 | University Health Network, TorontoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | recruiting | Phase 1 / Phase 2 | 99 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT01267955 | Vismodegib in Treating Patients With Advanced Chondrosarcomas | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07560410 | Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) | not yet recruiting | Phase 1 / Phase 2 | 10 | China Medical University HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04698785 | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients(REGOMAIN) | recruiting | Phase 2 | 36 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT02880319 | Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone | active not recruiting | Phase 2 | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07145931 | Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base | not yet recruiting | Phase 2 | 24 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT07066982 | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas(BAH2573-103) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04974008 | Osteosarcoma Maintenance Therapy With OST31-164(OST-164-01) | active not recruiting | Phase 2 | 39 | Emerald Clinical Inc.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT04963517 | Exercise Intervention for Bone Tumor Patients(proGAIT) | completed | Phase 2 / Phase 3 | 11 | Universität Duisburg-EssenOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06637007 | Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT05057130 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | unknown | Phase 2 / Phase 3 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04310410 | Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis(PRE-FURTHER) | completed | Phase 1 / Phase 2 | 10 | UMC UtrechtOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06074692 | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)(PRIMA) | recruiting | Phase 2 | 86 | Ruijin HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00667342 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | completed | Phase 2 | 43 | St. Jude Children's Research HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | completed | Phase 2 | 70 | Leiden University Medical CenterOTHER | 2 | Apr 20, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT03468075 | Gemcitabine Plus Ascorbate for Sarcoma in Adults | terminated | Phase 2 | 10 | Mohammed Milhem, MBBSOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02301039 | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | completed | Phase 2 | 144 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01313884 | Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | terminated | Phase 2 | 3 | Stanford UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | unknown | Phase 2 | 60 | Assaf-Harofeh Medical CenterOTHER_GOV | 0 | Nov 1, 2017 | clinicaltrials |
| NCT01085565 | Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System | completed | Phase 2 | 50 | InSightecINDUSTRY | 1 | Mar 8, 2016 | clinicaltrials |
| NCT00474994 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | completed | Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00516295 | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2014 | clinicaltrials |
| NCT00031915 | Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01830153 | RAD001 in Advanced Sarcoma | completed | Phase 2 | 41 | Asan Medical CenterOTHER | 1 | Apr 12, 2013 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
Data updated 9 hours agoSource updated Sep 29, 2026source: clinicaltrials